業績

2010年度 :: 著書・雑誌 :: 英文 :: 原著 :: 業績

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A.

J Clin Oncol. 28: 1904-1910. 2010. 4.

Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.

Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Sato A, Koizumi W, Mizunuma N, Takiuchi H.

Jpn J Clin Oncol. 40: 913-920. 2010. 5.

An embryo-specific expressing TGF-β family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma.

Ehira N, Oshiumi H, Matsumoto M, Kondo T, Asaka M, Seya T.

J Exp Clin Cancer Res. 29: 135. 2010. 10.

ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses.

Hayakawa S, Shiratori S, Yamato H, Kameyama T, Kitatsuji C, Kashigi F, Goto S, Kameoka S, Fujikura D, Yamada T, Mizutani T, Kazumata M, Sato M, Tanaka J, Asaka M, Ohba Y, Miyazaki T, Imamura M, Takaoka A.

Nat Immunol. 12: 37-44. 2011. 1.

Sensitive assay for the quantification of hepatitis B virus mutants by a minor groove binder probe and peptide nucleic acids.

Hige S, Yamamoto Y, Yoshida S, Kobayashi T, Horimoto H, Yamamoto K, Sho T, Natsuizaka M, Nakanishi M, Chuma M, Asaka M.

J Clin Microbiol. 48: 4487-4494. 2010. 12.

The feasibility for Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.

Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, Nakatsugawa M, Tamura Y, Kamiguchi K, Tsuruma T, Terui T, Ishitani K, Hashino S, Qiang Wang, Mark I Greene, Hasegawa T, Hirata K, Asaka M, Sato N.
The feasibility for Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.

Exp Mol Pathol. 90: 55-60. 2011. 2.

Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.

Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K.

Blood. 116: 1211-1219. 2010. 8.

Pathophysiological classification of functional dyspepsia using a novel drinking-ultrasonography test.

Kato M, Nishida U, Nishida M, Hata T, Asaka R, Haneda M, Yamamoto K, Imai A, Yoshida T, Ono S, Shimizu Y, Asaka M.

Digestion. 82: 162-166. 2010. 6.

Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: A randomized, double-blinded, placebo controlled study.

Kato M, Kamada G, Yamamoto K, Nishida U, Imai A, Yoshida T, Ono S, Nakagawa M, Nakagawa S, Shimizu Y, Asaka M.

J Gastroenterol Hepatol. 25: 1631-1635. 2010. 10.

IgG4-related sclerosing cholangitis and autoimmune pancreatitis: Histological assessment of biopsies from Vater's ampulla and the bile duct.

Kawakami H, Zen Y, Kuwatani M, Etoh K, Haba S, Yamato H, Shinada K, Kubota K, Asaka M.

J Gastroenterol Hepatol. 25: 1648-1655. 2010. 10.

Endoscopic nasobiliary drainage is most suitable for preoperative management in patients with hilar cholangiocarcinoma.

Kawakami H, Kuwatani M, Onodera M, Haba S, Eto K, Tanaka E, Hirano S, Kondo S, Asaka M.

J Gastroenterol. 46: 242-248. 2011. 2.

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.

Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M.

Int J Hematol. 92: 481-489. 2010. 10.

Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.

Kinoshita Y, Ashida K, Hongo M, Takeda H, Kato M, Shimizu Y, Nakagawa S, Nishi K, Yamauchi M, Eda Y, Ohara S, Koike T, Iijima K, Abe Y, Kusano M, Kawamura O, Shimoyama Y, Sekine C, Miwa J, Uemura N, Akiyama J, Furuta T, Shirai N, Niwa Y, Joh T, Kataoka H, Sasaki M, Wada T, Tanida S, Oshima T, Kasugai K, Konagaya T, Tokura Y, Mitsufuji S, Senoo H, Fujiwara Y, Ashida K, Fukuchi T, Habu Y, Sakaguchi M, Inoue K, Adachi K, Furuta K, Tari A, Tani H, Ishii Y, Shimatani T, Inoue M, Tanaka S, Kitadai Y, Ito M, Hiyama T, Yoshida S, Oka S, Manabe N, Ueno Y, Yoshida T, Ryozawa S, Harada T, Fuji T, Harima K, Murakami A, Nishimura S, Kawamura S, Kuniyoshi N, Kuniyoshi K, Matsui T, Noda T, Umezu T, Koganemaru F, Fujimoto K, Iwakiri R.

Aliment Pharmacol Ther. 33: 213-214. 2011. 1.

p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5.

Kobayashi T, Ishida J, Musashi M, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, Itoh H, Edamatsu H, Sutherland LC, Brachman RK.

Int J Cancer. 128: 304-318. 2011. 1.

Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.

Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M.

Adv Ther. 27: 483-492. 2010. 6.

A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.

Mizutani T, Kondo T, Darmanin S, Tsuda M, Tanaka S, Tobiume M, Asaka M, Ohba Y.

Clin Cancer Res. 16: 3964-3975. 2010. 8.

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.

Lancet Oncol. 11: 853-860. 2010. 8.

Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction.

Nema H, Kato M.

J Gastroenterol Hepatol. 25: S119-S121. 2010. 5.

Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.

Nema H, Kato M.

World J Gastroenterol. 42: 5342-5346. 2010. 11.

Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.

Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka N, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K.

Blood. 116: 4368-4375. 2010. 11.

Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission.

Nishiwaki S, Inamoto Y, Imamura M, Tsurumi H, Hatanaka K, Kawa K, Suzuki R, Miyamura K.

Blood. 117: 3698-3699. 2011. 3.

DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis.

Ohkawara T, Koyama Y, Onodera S, Takeda H, Kato M, Asaka M, Nishihira J.

Clin Exp Immunol. 163: 113-122. 2011. 1.

Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.

Okusaka T, Furuse J, Funakoshi A, Ioka T, Yamao K, Ohkawa S, Boku N, Komatsu Y, Nakamori S, Iguchi H, Ito T, Nakagawa K, Nakachi K.

Cancer Sci. 102: 425-431. 2011. 2.

Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer.

Ono S, Kato M, Takagi K, Kodaira J, Kubota K, Matsuno Y, Komatsu Y, Asaka M.

J Gastroenterol Hepatol. 25: 804-809. 2010. 4.

Evaluation of therapeutic effects and serious complications following endoscopic obliterative therapy with Histoacryl.

Sato T, Yamazaki K.

Clin Exp Gastroenterol. 3: 91-95. 2010. 7.

Retrospective analysis of endoscopic injection sclerotherapy for rectal varices compared with band ligation.

Sato T, Yamazaki K, Akaike J, Toyota J, Karino Y, Ohmura T.

Clin Exp Gastroenterol. 3: 159-163. 2010. 12.

Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen.

Shigematsu A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Yamaguchi K, Wakasa K, Takahata M, Goto H, Ito S, Takemura R, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.

Transpl Infect Dis. 12: 412-420. 2010. 10.

Signaling from fibroblast growth factor receptor 2 in immature hematopoietic cells facilitates donor hematopoiesis after intra-bone marrow-bone marrow transplantation.

Shigematsu A, Shi M, Okigaki M, Adachi Y, Koike N, Che J, Iwasaki M, Matsubara H, Imamura M, Ikehara S.

Stem Cells Dev. 19: 1679-1689. 2010. 11.

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.

Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Komatsu Y, Yuki S, Yoshida M, Takiuchi H, Utsunomiya S, Yatabe Y, Muro K.

Jpn J Clin Oncol. 40: 699-701. 2010. 4.

Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.

Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J, Shigematsu A, Kondo T, Yamamoto S, Endo T, Nishio M, Ito YM, Tanaka J, Koike T, Asaka M, Imamura M.

Am J Hematol. 85: 243-248. 2010. 4.

Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization.

Tsuchiya K, Hida K, Hida Y, Muraki C, Ohga N, Akino T, Kondo T, Miseki T, Nakagawa K, Shindoh M, Harabayashi T, Shinohara N, Nonomura K, Kobayashi M.

Int J Oncol. 36: 1379-1386. 2010. 6.

Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.

Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M.

Leuk Lymphoma. 50: 813-821. 2010. 5.

>